{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:11:33Z","timestamp":1790057493907,"version":"4.0.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2003]]},"DOI":"10.1007\/s10156-003-0279-x","type":"journal-article","created":{"date-parts":[[2004,1,22]],"date-time":"2004-01-22T11:39:55Z","timestamp":1074771595000},"page":"292-296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"title":["Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling"],"prefix":"10.1016","volume":"9","author":[{"given":"David P.","family":"Nicolau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10 (Suppl 2)","key":"10.1007\/s10156-003-0279-X_bib0005","first-page":"525","article-title":"Optimizing antimicrobial therapy and emerging pathogens","volume":"4","author":"Nicolau","year":"1998","journal-title":"Am J Man Care"},{"key":"10.1007\/s10156-003-0279-X_bib0010","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0732-8893(00)00185-1","article-title":"The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae","volume":"38","author":"Ambrose","year":"2000","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1007\/s10156-003-0279-X_bib0015","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1128\/AAC.45.12.3468-3473.2001","article-title":"Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis","volume":"45","author":"Montgomery","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 9A","key":"10.1007\/s10156-003-0279-X_bib0020","doi-asserted-by":"crossref","first-page":"13S","DOI":"10.1016\/S0002-9343(01)01026-9","article-title":"Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae","volume":"111","author":"Nicolau","year":"2001","journal-title":"Am J Med"},{"key":"10.1007\/s10156-003-0279-X_bib0025","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1128\/AAC.46.2.586-589.2002","article-title":"Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and Monte Carlo simulation","volume":"46","author":"Drusano","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s10156-003-0279-X_bib0030","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/ajhp\/60.6.565","article-title":"Economic benefit of a meropenem dosage strategy based on pharmacodynamic concepts","volume":"60","author":"Kuti","year":"2003","journal-title":"Am J Health System Pharmacy"},{"key":"10.1007\/s10156-003-0279-X_bib0035","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00006454-199603000-00015","article-title":"Pharmacokinetics and pharmacodynamics of antibiotics in otitis media","volume":"15","author":"Craig","year":"1996","journal-title":"Pediatr Infect Dis J"},{"issue":"Suppl 3","key":"10.1007\/s10156-003-0279-X_bib0040","first-page":"38","article-title":"Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections","volume":"9","author":"Drusano","year":"1997","journal-title":"J Chemother"},{"key":"10.1007\/s10156-003-0279-X_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rational for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1007\/s10156-003-0279-X_bib0050","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1001\/jama.279.2.125","article-title":"Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials","volume":"279","author":"Preston","year":"1998","journal-title":"JAMA"},{"key":"10.1007\/s10156-003-0279-X_bib0055","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/00001432-200104000-00010","article-title":"Pharmacokinetic and pharmacodynamic properties of antimicrobials in the therapy of respiratory tract infections","volume":"14","author":"Andes","year":"2001","journal-title":"Curr Opin Infect Dis"},{"issue":"Suppl 2","key":"10.1007\/s10156-003-0279-X_bib0060","first-page":"S27","article-title":"Pharmacokinetics and pharmacodynamics of fluoroquinolones","volume":"4","author":"Drusano","year":"1998","journal-title":"Clin Microbiol Infect"},{"key":"10.1007\/s10156-003-0279-X_bib0065","series-title":"In vivo pharmacodynamic activity of HMR 3647, a new ketolide (abstract)","author":"Vesga","year":"1997"},{"key":"10.1007\/s10156-003-0279-X_bib0070","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/infdis\/155.1.93","article-title":"Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration","volume":"155","author":"Moore","year":"1987","journal-title":"J Infect Dis"},{"key":"10.1007\/s10156-003-0279-X_bib0075","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1128\/AAC.43.3.623","article-title":"Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria","volume":"43","author":"Kashuba","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s10156-003-0279-X_bib0080","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1128\/AAC.37.5.1073","article-title":"Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients","volume":"37","author":"Forrest","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s10156-003-0279-X_bib0085","series-title":"In vivo pharmacodynamic activity of gatifloxacin against multiple bacterial pathogens (abstract)","author":"Andes","year":"1999"},{"key":"10.1007\/s10156-003-0279-X_bib0090","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1128\/AAC.43.3.672","article-title":"Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection","volume":"43","author":"Lacy","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s10156-003-0279-X_bib0095","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/jac\/43.1.79","article-title":"Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae","volume":"43","author":"Lister","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1007\/s10156-003-0279-X_bib0100","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/jac\/45.4.437","article-title":"In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin","volume":"45","author":"Fung-Tomc","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1007\/s10156-003-0279-X_bib0105","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1128\/AAC.44.12.3351-3356.2000","article-title":"Antibacterial spectrum of a novel desfluoro(6) quinolone","volume":"44","author":"Fung-Tomc","year":"2000","journal-title":"BMS-284756. Antimicrob Agents Chemother"},{"key":"10.1007\/s10156-003-0279-X_bib0110","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1128\/AAC.45.10.2793-2797.2001","article-title":"Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections","volume":"45","author":"Ambrose","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s10156-003-0279-X_bib0115","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1128\/AAC.45.7.2092-2097.2001","article-title":"Pharmacodynamic assessment of gatifloxacin against Streptococcus pneumoniae","volume":"45","author":"Mattoes","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s10156-003-0279-X_bib0120","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00003088-199528020-00005","article-title":"The importance of pharmacokinetic\/pharmacodynamic surrogate markers to outcome","volume":"28","author":"Hyatt","year":"1995","journal-title":"Focus on antibacterial agents. Clin Pharmacokinetics"},{"issue":"Suppl 1","key":"10.1007\/s10156-003-0279-X_bib0125","first-page":"21","article-title":"Pharmacodynamic considerations in the selection of antibiotics for respiratory tract infections: Focus on the fluoroquinolones","volume":"3","author":"Grant","year":"1999","journal-title":"Antibiotics for Clinicians"},{"key":"10.1007\/s10156-003-0279-X_bib0130","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0732-8893(95)00053-D","article-title":"Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins","volume":"22","author":"Craig","year":"1995","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1007\/s10156-003-0279-X_bib0135","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1128\/AAC.44.5.1291-1295.2000","article-title":"Pharmacodynamic assessment of cefprozil against Streptococcus pneumoniae: implications for breakpoint determinations","volume":"44","author":"Nicolau","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s10156-003-0279-X_bib0140","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1592\/phco.23.8.988.32878","article-title":"Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion","volume":"23","author":"Dandekar","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1007\/s10156-003-0279-X_bib0145","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/0002-9343(79)90242-0","article-title":"A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients","volume":"67","author":"Bodey","year":"1979","journal-title":"Am J Med"},{"key":"10.1007\/s10156-003-0279-X_bib0150","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1592\/phco.22.7.471.33665","article-title":"Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital","volume":"22","author":"Grant","year":"2002","journal-title":"J Pharmacother"},{"key":"10.1007\/s10156-003-0279-X_bib0155","series-title":"Antipneumococcal activity of telithromycin against 294 pneumococci from ten central and eastern European Countries (abstract)","author":"Appelbaum","year":"2000"},{"issue":"Suppl 1","key":"10.1007\/s10156-003-0279-X_bib0160","first-page":"319","article-title":"Utility of an 800-mg dose of telithromycin for CAP caused by extracellular pathogens: a preliminary assessment by pharmacodynamic modeling and Monte Carlo simulation (abstract)","volume":"8","author":"Drusano","year":"2002","journal-title":"Clin Microbiol Infect"},{"key":"10.1007\/s10156-003-0279-X_bib0165","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/jac\/49.1.31","article-title":"Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence","volume":"49","author":"Ball","year":"2002","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X04711058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X04711058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s10156-003-0279-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:43:08Z","timestamp":1761158588000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X04711058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003]]}},"alternative-id":["S1341321X04711058"],"URL":"https:\/\/doi.org\/10.1007\/s10156-003-0279-x","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2003]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s10156-003-0279-X","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2003 Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}